Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer
{{output}}
Although the recently approved prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) [177Lu]Lu-PSMA-617 has improved outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC), not all patients respond optimally t... ...
